176 related articles for article (PubMed ID: 30631747)
21. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
[TBL] [Abstract][Full Text] [Related]
23. A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer.
Cazes A; Betancourt O; Esparza E; Mose ES; Jaquish D; Wong E; Wascher AA; Tiriac H; Gymnopoulos M; Lowy AM
Clin Cancer Res; 2021 Apr; 27(7):2100-2110. PubMed ID: 33451980
[TBL] [Abstract][Full Text] [Related]
24. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
Willuda J; Linden L; Lerchen HG; Kopitz C; Stelte-Ludwig B; Pena C; Lange C; Golfier S; Kneip C; Carrigan PE; Mclean K; Schuhmacher J; von Ahsen O; Müller J; Dittmer F; Beier R; El Sheikh S; Tebbe J; Leder G; Apeler H; Jautelat R; Ziegelbauer K; Kreft B
Mol Cancer Ther; 2017 May; 16(5):893-904. PubMed ID: 28292941
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
26. Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer.
Majeed S; Aparnathi MK; Nixon KCJ; Venkatasubramanian V; Rahman F; Song L; Weiss J; Barayan R; Sugumar V; Barghout SH; Pearson JD; Bremner R; Schimmer AD; Tsao MS; Liu G; Lok BH
Clin Cancer Res; 2022 May; 28(9):1966-1978. PubMed ID: 35165102
[TBL] [Abstract][Full Text] [Related]
27. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
Kumar S; Schoonderwoerd MJA; Kroonen JS; de Graaf IJ; Sluijter M; Ruano D; González-Prieto R; Verlaan-de Vries M; Rip J; Arens R; de Miranda NFCC; Hawinkels LJAC; van Hall T; Vertegaal ACO
Gut; 2022 Nov; 71(11):2266-2283. PubMed ID: 35074907
[TBL] [Abstract][Full Text] [Related]
28. Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.
Henderson SE; Ding LY; Mo X; Bekaii-Saab T; Kulp SK; Chen CS; Huang PH
Neoplasia; 2016 Dec; 18(12):765-774. PubMed ID: 27889645
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
[TBL] [Abstract][Full Text] [Related]
30. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping.
Khera E; Cilliers C; Smith MD; Ganno ML; Lai KC; Keating TA; Kopp A; Nessler I; Abu-Yousif AO; Thurber GM
Neoplasia; 2021 Feb; 23(2):210-221. PubMed ID: 33385970
[TBL] [Abstract][Full Text] [Related]
31. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS
Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082
[TBL] [Abstract][Full Text] [Related]
32. Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility.
Satomaa T; Pynnönen H; Vilkman A; Kotiranta T; Pitkänen V; Heiskanen A; Herpers B; Price LS; Helin J; Saarinen J
Antibodies (Basel); 2018 Mar; 7(2):. PubMed ID: 31544867
[TBL] [Abstract][Full Text] [Related]
33. Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer.
Cao R; Song W; Ye C; Liu X; Li L; Li Y; Yao H; Zhou X; Li L; Shao R
Cancer Med; 2019 Feb; 8(2):643-655. PubMed ID: 30681288
[TBL] [Abstract][Full Text] [Related]
34. Generation and application of patient-derived xenograft models in pancreatic cancer research.
Wang CF; Shi XJ
Chin Med J (Engl); 2019 Nov; 132(22):2729-2736. PubMed ID: 31725451
[TBL] [Abstract][Full Text] [Related]
35. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.
Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P
Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
37. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma.
Hartman SJ; Bagby SM; Yacob BW; Simmons DM; MacBeth M; Lieu CH; Davis SL; Leal AD; Tentler JJ; Diamond JR; Eckhardt SG; Messersmith WA; Pitts TM
Front Oncol; 2021; 11():642328. PubMed ID: 33869031
[TBL] [Abstract][Full Text] [Related]
38. Patient Derived Xenografts Expand Human Primary Pancreatic Tumor Tissue Availability for
Brock RM; Beitel-White N; Coutermarsh-Ott S; Grider DJ; Lorenzo MF; Ringel-Scaia VM; Manuchehrabadi N; Martin RCG; Davalos RV; Allen IC
Front Oncol; 2020; 10():843. PubMed ID: 32528898
[TBL] [Abstract][Full Text] [Related]
39. Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients.
Roche S; O'Neill F; Murphy J; Swan N; Meiller J; Conlon NT; Geoghegan J; Conlon K; McDermott R; Rahman R; Toomey S; Straubinger NL; Straubinger RM; O'Connor R; McVey G; Moriarty M; Clynes M
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32024004
[TBL] [Abstract][Full Text] [Related]
40. Activated matriptase as a target to treat breast cancer with a drug conjugate.
Rather GM; Lin SY; Lin H; Banach-Petrosky W; Hirshfield KM; Lin CY; Johnson MD; Szekely Z; Bertino JR
Oncotarget; 2018 May; 9(40):25983-25992. PubMed ID: 29899836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
